Oral treatment with Bifidobacterium longum 51A reduced inflammation in a murine experimental model of gout

Beneficial Microbes

Volumn 6, Issue 6, 2015, Pages 799-806

  Vieira, A T ^a   Galvao I ^a   Amaral, F A ^a   Teixeira, M M ^a   Nicoli, J R ^a   Martins, F S ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Bifidobacterium; Gout; Inflammation; Probiotics

Indexed keywords

BIFIDOBACTERIUM LONGUM 51A PROBIOTIC AGENT; CXCL1 CHEMOKINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; MYELOPEROXIDASE; PROBIOTIC AGENT; UNCLASSIFIED DRUG; URATE; URIC ACID; ANTIGOUT AGENT; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BIFIDOBACTERIUM LONGUM; CONTROLLED STUDY; CRYSTAL; ENZYME ACTIVITY; GOUT; IMMUNE RESPONSE; INFLAMMATION; KNEE; LEUKOCYTE ACTIVATION; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PERIARTICULAR JOINT DISEASE; TISSUE INJURY; ANIMAL; BIFIDOBACTERIUM; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; ORAL DRUG ADMINISTRATION; PATHOLOGY; SYNOVIAL FLUID;

ADMINISTRATION, ORAL; ANIMALS; BIFIDOBACTERIUM; CYTOKINES; DISEASE MODELS, ANIMAL; GOUT; GOUT SUPPRESSANTS; INFLAMMATION; MICE, INBRED C57BL; PROBIOTICS; SYNOVIAL FLUID; URIC ACID;

EID: 84949780184     PISSN: 18762883     EISSN: 18762891     Source Type: Journal    
DOI: 10.3920/BM2015.0015     Document Type: Article

References (47)

1. Al-Okbi, S.Y., 2011. Role of Bifidobacterium bifidum and plant food extracts in improving microflora and biochemical and cytogenetic parameters in adjuvant arthritis. Grasas y Aceites 62: 12.
2. Amaral, F.A., Costa, V.V., Tavares, L.D., Sachs, D., Coelho, F.M., Fagundes, C.T., Soriani, F.M., Silveira, T.N., Cunha, L.D., Zamboni, D.S., Quesniaux, V., Peres, R.S., Cunha, T.M., Cunha, F.Q., Ryffel, B., Souza, D.G. and Teixeira, M.M., 2012. NLRP3 inflammasome-mediated neutrophil recruitment and hypernociception depend on leukotriene B(4) in a murine model of gout. Arthritis and Rheumatism 64: 474-484.
3. Arpaia, N., Campbell, C., Fan, X., Dikiy, S., Van der Veeken, J., deRoos, P., Liu, H., Cross, J.R., Pfeffer, K., Coffer, P.J. and Rudensky, A.Y., 2013. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504: 451-455.
4. Bardin, T. and Richette, P., 2014. Definition of hyperuricemia and gouty conditions. Current Opinion in Rheumatology 26: 186-191.
5. Busso, N. and So, A., 2010. Mechanisms of inflammation in gout. Arthritis Research and Therapy 12: 206.
6. Chen, Y.H., Hsieh, S.C., Chen, W.Y., Li, K.J., Wu, C.H., Wu, P.C., Tsai, C.Y. and Yu, C.L., 2011. Spontaneous resolution of acute gouty arthritis is associated with rapid induction of the anti-inflammatory factors TGFbeta1, IL-10 and soluble TNF receptors and the intracellular cytokine negative regulators CIS and SOCS3. Annals of the Rheumatic Diseases 70: 1655-1663.
7. Coelho, F.M., Pinho, V., Amaral, F.A., Sachs, D., Costa, V.V., Rodrigues, D.H., Vieira, A.T., Silva, T.A., Souza, D.G., Bertini, R., Teixeira, A.L. and Teixeira, M.M., 2008. The chemokine receptors CXCR1/CXCR2 modulate antigen-induced arthritis by regulating adhesion of neutrophils to the synovial microvasculature. Arthritis and Rheumatism 58: 2329-2337.
8. Eerola, E., Mottonen, T., Hannonen, P., Luukkainen, R., Kantola, I., Vuori, K., Tuominen, J. and Toivanen, P., 1994. Intestinal flora in early rheumatoid arthritis. British Journal of Rheumatology 33: 1030-1038.
9. Foligne, B., Nutten, S., Grangette, C., Dennin, V., Goudercourt, D., Poiret, S., Dewulf, J., Brassart, D., Mercenier, A. and Pot, B., 2007. Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World Journal of Gastroenterology 13: 236-243.
10. Fukuda, S., Toh, H., Hase, K., Oshima, K., Nakanishi, Y., Yoshimura, K., Tobe, T., Clarke, J.M., Topping, D.L., Suzuki, T., Taylor, T.D., Itoh, K., Kikuchi, J., Morita, H., Hattori, M. and Ohno, H., 2011. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 469: 543-547.
11. Guerra, P.V., Lima, L.N., Souza, T.C., Mazochi, V., Penna, F.J., Silva, A.M., Nicoli, J.R. and Guimaraes, E.V., 2011. Pediatric functional constipation treatment with Bifidobacterium-containing yogurt: a crossover, double-blind, controlled trial. World Journal of Gastroenterology 17: 3916-3921.
12. Hachicha, M., Naccache, P.H. and McColl, S.R., 1995. Inflammatory microcrystals differentially regulate the secretion of macrophage inflammatory protein 1 and interleukin 8 by human neutrophils: a possible mechanism of neutrophil recruitment to sites of inflammation in synovitis. Journal of Experimental Medicine 182: 2019-2025.
13. Harrold, L.R., Yood, R.A., Mikuls, T.R., Andrade, S.E., Davis, J., Fuller, J., Chan, K.A., Roblin, D., Raebel, M.A., Von Worley, A., Platt, R. and Saag, K.G., 2006. Sex differences in gout epidemiology: evaluation and treatment. Annals of the Rheumatic Diseases 65: 1368-1372.
14. Hatakka, K., Martio, J., Korpela, M., Herranen, M., Poussa, T., Laasanen, T., Saxelin, M., Vapaatalo, H., Moilanen, E. and Korpela, R., 2003. Effects of probiotic therapy on the activity and activation of mild rheumatoid arthritis - a pilot study. Scandinavian Journal of Rheumatology 32: 211-215.
15. Homayouni Rad, A., Torab, R., Ghalibaf, M., Norouzi, S. and Mehrabany, E.V., 2013. Might patients with immune-related diseases benefit from probiotics? Nutrition 29: 583-586.
16. Kobayashi, Y., 2008. The role of chemokines in neutrophil biology. Frontiers in Bioscience 13: 2400-2407.
17. Lebeer, S., Vanderleyden, J. and De Keersmaecker, S.C., 2010. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nature Reviews Microbiology 8: 171-184.
18. Lee, S.J., Hirsch, J.D., Terkeltaub, R., Khanna, D., Singh, J.A., Sarkin, A. and Kavanaugh, A., 2009. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology 48: 582-586.
19. Martin, W.J. and Harper, J.L., 2010. Innate inflammation and resolution in acute gout. Immunology and Cell Biology 88: 15-19.
20. Martin, W.J., Herst, P.M., Chia, E.W. and Harper, J.L., 2009. Sesquiterpene dialdehydes inhibit MSU crystal-induced superoxide production by infiltrating neutrophils in an in vivo model of gouty inflammation. Free Radical Biology and Medicine 47: 616-621.
21. Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. and Tschopp, J., 2006. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440: 237-241.
22. Maslowski, K.M. and Mackay, C.R., 2011. Diet, gut microbiota and immune responses. Nature Immunology 12: 5-9.
23. Maslowski, K.M., Vieira, A.T., Ng, A., Kranich, J., Sierro, F., Yu, D., Schilter, H.C., Rolph, M.S., Mackay, F., Artis, D., Xavier, R.J., Teixeira, M.M. and Mackay, C.R., 2009. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461: 1282-1286.
24. Nathan, C., 2006. Neutrophils and immunity: challenges and opportunities. Nature Reviews Immunology 6: 173-182.
25. Perez, D.A., Vago, J.P., Athayde, R.M., Reis, A.C., Teixeira, M.M., Sousa, L.P. and Pinho, V., 2014. Switching off key signaling survival molecules to switch on the resolution of inflammation. Mediators of Inflammation 2014: 829851.
26. Picard, C., Fioramonti, J., Francois, A., Robinson, T., Neant, F. and Matuchansky, C., 2005. Review article: bifidobacteria as probiotic agents - physiological effects and clinical benefits. Alimentary Pharmacology and Therapeutics 22: 495-512.
27. Pineda Mde, L., Thompson, S.F., Summers, K., de Leon, F., Pope, J. and Reid, G., 2011. A randomized, double-blinded, placebo-controlled pilot study of probiotics in active rheumatoid arthritis. Medical Science Monitor 17: CR347-354.
28. Popa-Nita, O. and Naccache, P.H., 2010. Crystal-induced neutrophil activation. Immunology and Cell Biology 88: 32-40.
29. Rees, F., Hui, M. and Doherty, M., 2014. Optimizing current treatment of gout. Nature Reviews Rheumatology 10: 271-283.
30. Reid, G., Jass, J., Sebulsky, M.T. and McCormick, J.K., 2003. Potential uses of probiotics in clinical practice. Clinical Microbiology Reviews 16: 658-672.
31. Robinson, P.C. and Horsburgh, S., 2014. Gout: joints and beyond, epidemiology, clinical features, treatment and co-morbidities. Maturitas 78: 245-251.
32. Roddy, E. and Choi, H.K., 2014. Epidemiology of gout. Rheumatic Diseases Clinics of North America 40: 155-175.
33. Roddy, E. and Doherty, M., 2010. Epidemiology of gout. Arthritis Research and Therapy 12: 223.
34. Roddy, E., Zhang, W. and Doherty, M., 2007a. The changing epidemiology of gout. Nature Clinical Practice: Rheumatology 3: 443-449.
35. Roddy, E., Zhang, W. and Doherty, M., 2007b. Is gout associated with reduced quality of life? A case-control study. Rheumatology 46: 1441-1444.
36. Sachs, D., Coelho, F.M., Costa, V.V., Lopes, F., Pinho, V., Amaral, F.A., Silva, T.A., Teixeira, A.L., Souza, D.G. and Teixeira, M.M., 2011. Cooperative role of tumour necrosis factor-alpha, interleukin-1beta and neutrophils in a novel behavioural model that concomitantly demonstrates articular inflammation and hypernociception in mice. British Journal of Pharmacology 162: 72-83.
37. Scher, J.U. and Abramson, S.B., 2011. The microbiome and rheumatoid arthritis. Nature Reviews Rheumatology 7: 569-578.
38. Serhan, C.N., Brain, S.D., Buckley, C.D., Gilroy, D.W., Haslett, C., O'Neill, L.A., Perretti, M., Rossi, A.G. and Wallace, J.L., 2007. Resolution of inflammation: state of the art, definitions and terms. FASEB Journal 21: 325-332.
39. Shida, K., Nanno, M. and Nagata, S., 2011. Flexible cytokine production by macrophages and T cells in response to probiotic bacteria: a possible mechanism by which probiotics exert multifunctional immune regulatory activities. Gut Microbes 2: 109-114.
40. Souza, T.C., Silva, A.M., Drews, J.R., Gomes, D.A., Vinderola, C.G. and Nicoli, J.R., 2013. In vitro evaluation of Bifidobacterium strains of human origin for potential use in probiotic functional foods. Beneficial Microbes 4: 179-186.
41. Souza, T.C., Zacarias, M.F., Silva, A.M., Binetti, A., Reinheimer, J., Nicoli, J.R. and Vinderola, G., 2012. Cell viability and immunostimulating and protective capacities of Bifidobacterium longum 51A are differentially affected by technological variables in fermented milks. Journal of Applied Microbiology 112: 1184-1192.
42. Terkeltaub, R., 2009. Gout. Novel therapies for treatment of gout and hyperuricemia. Arthritis Research and Therapy 11: 236.
43. Terkeltaub, R.A. and Ginsberg, M.H., 1988. The inflammatory reaction to crystals. Rheumatic Diseases Clinics of North America 14: 353-364.
44. Vaahtovuo, J., Munukka, E., Korkeamaki, M., Luukkainen, R. and Toivanen, P., 2008. Fecal microbiota in early rheumatoid arthritis. Journal of Rheumatology 35: 1500-1505.
45. Vieira, A.T., Macia, L., Galvao, I., Martins, F.S., Cecilia, M., Canesso, C., Amaral, F.A., Garcia, C.C., Maslowski, K.M., De Leon, E., Shim, D., Nicoli, J., Harper, J.L., Teixeira, M.M. and Mackay, C.R., 2015. A role for the gut microbiota and the metabolite sensing receptor GPR43 in a murine model of gout. Arthritis and Rheumatology 67: 1646-1656.
46. Vieira, A.T., Teixeira, M.M. and Martins, F.S., 2013. The role of probiotics and prebiotics in inducing gut immunity. Frontiers in Immunology 4: 445.
47. Wu, H.J., Ivanov, II, Darce, J., Hattori, K., Shima, T., Umesaki, Y., Littman, D.R., Benoist, C. and Mathis, D., 2010. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 32: 815-827.